Threshold Pharmaceuticals (THLD)

Business description

Threshold is focused on tumour hypoxia, a low-oxygen condition found in most solid tumours and some blood cancers. Evofosfamide is in Ph III for STS and pancreatic cancer and earlier trials in other cancers. It is partnered with Merck KGaA.

TH-302 Phase II GBM plans confirmed

QuickView | Pharmaceutical & healthcare | 18/11/2014

Additional interim data from the ongoing Phase I/II investigator-led trial of Threshold’s TH-302 in glioblastoma (GBM) have been reported at the SNO (society for neuro-oncology) conference. Based on the early signs of efficacy observed, with survival exceeding historic reference data, plans for an investigator-led, two-centre Phase II trial have now been confirmed, supported by an FDA grant. GBM could be an indication eligible for accelerated development, given the unmet medical need.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.US$35.6m
Last closeUS$0.498
High / Low (52 weeks)US$1.3 / US$0.4
Stock market listingUS
Forecast net cash (US$m)31
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual26.6(1.2)(2.6)
Relative *24.2(4.6)(14.3)

* % Relative to local index

Company news